Burzynski Research (BZYR) 0.1288 $BZYR
Anaplastic Astrocytoma - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv742d/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amgen Inc. - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - e-Therapeutics plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncovir, Inc. - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/cv742d/anaplastic
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 18, 8:30PM CDT
The report "Anaplastic Astrocytoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-a...eport.html .
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
Business Wire - Thu Jun 18, 2:09PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Patients with Non-Diffuse Intrinsic Pontine Glioma
Business Wire - Thu Apr 16, 5:46PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma
Business Wire - Tue Mar 31, 4:25PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
PR Newswire - Thu Mar 26, 5:51PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.
Burzynski Research Institute awarded US FDA's approval to begin new clinical trial in Diffuse Intrinsic Brainstem Glioma
M2 - Mon Oct 27, 6:20AM CDT
Biopharmaceutical company Burzynski Research Institute (Other OTC:BZYR) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > three months of age with a diffuse intrinsic brainstem glioma (DIPG), the most common brainstem tumor in children.
Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
PR Newswire - Fri Oct 24, 4:50PM CDT
Burzynski Research Institute, Inc. (BRI) announced today that the U.S. Food and Drug Administration (FDA) has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (greater-than or equal to 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor). The study is in its final organizational stage and will begin accruing patients as soon as this organizational stage is completed.
Anaplastic Astrocytoma - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv742d/anaplastic) has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amgen Inc. - Boehringer Ingelheim GmbH - Burzynski Research Institute, Inc. - Cavion LLC - e-Therapeutics plc - Eli Lilly and Company - Millennium Pharmaceuticals, Inc. - Novartis AG - Oncovir, Inc. - Orbus Therapeutics, Inc. - Pfizer Inc. - Sanofi - Tocagen Inc. - TVAX Biomedical, Inc. For more information visit http://www.researchandmarkets.com/research/cv742d/anaplastic
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 18, 8:30PM CDT
The report "Anaplastic Astrocytoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-a...eport.html .
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma
Business Wire - Thu Jun 18, 2:09PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Patients with Non-Diffuse Intrinsic Pontine Glioma
Business Wire - Thu Apr 16, 5:46PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain and brainstem tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma
Business Wire - Tue Mar 31, 4:25PM CDT
Burzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with rare brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal(R)) and Antineoplaston AS2-1 injections (Astugenal(R)). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives.
Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
PR Newswire - Thu Mar 26, 5:51PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.
Burzynski Research Institute awarded US FDA's approval to begin new clinical trial in Diffuse Intrinsic Brainstem Glioma
M2 - Mon Oct 27, 6:20AM CDT
Biopharmaceutical company Burzynski Research Institute (Other OTC:BZYR) revealed on Friday that it has received approval from the US Food and Drug Administration (FDA) to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > three months of age with a diffuse intrinsic brainstem glioma (DIPG), the most common brainstem tumor in children.
Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
PR Newswire - Fri Oct 24, 4:50PM CDT
Burzynski Research Institute, Inc. (BRI) announced today that the U.S. Food and Drug Administration (FDA) has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (greater-than or equal to 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor). The study is in its final organizational stage and will begin accruing patients as soon as this organizational stage is completed.
